Abstract
The present Industry Update covers the period 16 April–15 May 2012, which included the announcement of a major partnership between Merck & Co., and Endocyte for development of the latter’s folate-conjugated vinca alkaloid chemotherapeutic in a variety of folate receptor-expressing cancers. The deal includes the rights to a companion diagnostic imaging agent. Alnylam announced positive results from two of its siRNA clinical programs using a lipid nanoparticle delivery system. A number of players in the delivery space announced completion of successful funding rounds, including Egalet, Eleven, miRagen and Sutro, with over US$70 million raised. In addition cancer stem cell player, OncoMed, announced plans for a $115 million initial public offering. Israel-based Prolor shared plans to raise $32.5 million to help fund continued development of its long-acting hGH product candidate, for which positive Phase II data were announced.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
